Results 81 to 90 of about 7,461 (205)

Screening and prevention of anticoagulant resistance development in house mice: A review [PDF]

open access: yesPesticidi i Fitomedicina, 2020
Unrestricted use of anticoagulants has resulted in rodents developing resistance to them. This has caused a series of problems regarding reduction in rodent populations, which has further implicated great economic losses and a serious threat to the ...
Blažić Tanja   +2 more
doaj  

Warfarin Hipersensitivity. How to Deal with it? [PDF]

open access: yes, 2010
Os autores descrevem um caso clínico de hipersensibilidade à varfarina traduzido por uma elevação acentuada do INR, aquando da introdução do fármaco em doente com antecedentes tromboembólicos. Da pesquisa de polimorfismos para os genes VKORC1 e CYP2C9,
Borges, A, Lima, AF, Reis, J, Serrano, F
core  

Development and Validation of a Multigene Panel for Pharmacogenomics Testing Using Next‐Generation Sequencing for Routine Clinical Practice

open access: yesClinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Pharmacogenomics (PGx) is a rapidly evolving field that aims to personalize medicine by identifying genetic variations that influence drug response. While next‐generation sequencing (NGS)–based applications are not yet widely adopted in clinical routine, this study aimed to validate 9 genes of the NGS‐based Ion AmpliSeq Pharmacogenomics Panel ...
Yaowaluck Hongkaew   +7 more
wiley   +1 more source

Factors influencing vitamin K antagonists therapy / Factori care influențează terapia cu antagoniști ai vitaminei K

open access: yesRomanian Journal of Laboratory Medicine, 2015
Antagoniștii vitaminei K (AVK) sunt utilizați pe scară largă pentru profilaxia primară și secundară a trombembolismului, efectul lor anticoagulant fiind monitorizat prin intermediul INR.
Brudașcă Ioana
doaj   +1 more source

Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort

open access: yesClinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT The aim of this study was to describe self‐reported use of medications with established pharmacogenetic guidance in the Our Future Health (OFH) cohort. We examined four key pharmacogenes—CYP2C19, CYP2C9, CYP2D6, and SLCO1B1—and medications supported by strong evidence for clinical actionability according to the Clinical Pharmacogenetics ...
Padraig Dixon   +4 more
wiley   +1 more source

French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics

open access: yesFundamental &Clinical Pharmacology, Volume 40, Issue 1, January 2026.
ABSTRACT Background The implementation of pharmacogenetics in clinical practice increasingly relies on multigene panels. Objectives The objective of this study is to develop harmonized recommendations for the design and analytical implementation of multigene pharmacogenetic panels, defining clinically relevant genes and associated regions of interest ...
Nicolas Picard   +29 more
wiley   +1 more source

Characterization of the VKORC1 and CYP2C9 genotypes v2

open access: yes, 2023
Vitamin K antagonists are anticoagulants which represent widely prescribed drugs for prevention and treatment of thromboembolic disorders. The molecular target of these drugs is vitamin K epoxide reductase enzyme and their metabolism is performed by the cytochrome P-450 2C9 enzyme, both of which are encoded by polymorphic genes - vitamin K epoxide ...
Mirsada Causevic, Honours BSc, PhD   +1 more
openaire   +1 more source

NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma

open access: yesAdvanced Science, Volume 12, Issue 46, December 11, 2025.
High PIVKA‐II expression in HCC correlates with resistance to anti‐PD‐1 plus lenvatinib, driven by an immunosuppressive TME. NQO1/p65/CXCL12 axis recruits Tregs to promote resistance to anti‐PD‐1 plus lenvatinib in HCC with high PIVKA‐II expression.
Biao Gao   +18 more
wiley   +1 more source

The history and future of pharmacogenetics in Aotearoa/New Zealand

open access: yesJournal of the Royal Society of New Zealand, Volume 55, Issue 6, Page 2422-2439, December 2025.
ABSTRACT Pharmacogenetics is the study of genetic variants in genes which may impact on the outcome of drug treatment, either through safety considerations (occurrence of adverse drug reactions or therapeutic failure) or altered drug pharmacokinetics. This paper provides a brief history of pharmacogenetics research in the Aotearoa/New Zealand context ...
Martin A. Kennedy
wiley   +1 more source

Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs

open access: yesClinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Pharmacogenomic (PGx) testing using multi‐gene panels (mgPGx) is documented to improve clinical outcomes; however, real‐world data on its economic impact remain limited. This study aimed to evaluate the utility and economic value of mgPGx testing among Medicare patients within a community‐based health system.
Nihal El Rouby   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy